Global Paediatric Epilepsy Therapeutics Market – Industry Trends and Forecast to 2030

Análise e dimensão do mercado terapêutico para a epilepsia pediátrica

A ocorrência de crises epilépticas é maior nos países de baixo a médio rendimento, o que impulsiona a procura de tratamento das crises epilépticas nos países altamente desenvolvidos. De acordo com a Epilepsy Foundation, apenas cerca de 25% das pessoas que têm Status Epilepticus terão epilepsia. Além disso, em muitos casos, acontece com crianças com menos de 15 anos e adultos com mais de 40 anos. Existem inúmeras complicações da epilepsia que podem variar desde a ausência de complicações até à morte.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado de terapêutica para a epilepsia pediátrica no período de previsão 2023-2030. O CAGR esperado do mercado terapêutico para a epilepsia pediátrica tende a rondar os 5% no período de previsão mencionado. O mercado foi avaliado em 11,45 mil milhões de dólares em 2022 e cresceria para 16,91 mil milhões de dólares até 2030. Além dos insights de mercado, como o valor de mercado, taxa de crescimento, segmentos de mercado, cobertura geográfica, participantes no mercado e cenário de mercado, o relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge também inclui análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de terapêutica para a epilepsia pediátrica

Definição de mercado

A epilepsia é tipicamente considerada uma perturbação neurológica crónica que pode causar convulsões recorrentes não provocadas, seguidas de episódios indetetáveis ​​de movimentos involuntários. As principais causas podem ser infeções, mutações genéticas, lesões cerebrais e um tumor que leva ao desenvolvimento anormal de vasos sanguíneos e hemorragia no cérebro das crianças. As crianças que sofrem de autismo, síndrome de Down e outros distúrbios metabólicos podem ter epilepsia. Os sintomas incluem movimentos bruscos incontroláveis, confusão temporária, medo, ansiedade e outros.

Dinâmica do mercado terapêutico para a epilepsia pediátrica

Motoristas

• Incidência crescente de distúrbios neurológicos

Espera-se que o aumento da ocorrência de epilepsia e o aumento da incidência de distúrbios neurológicos aumentem a procura de terapêutica para a epilepsia pediátrica, o que deverá impulsionar o crescimento do mercado durante o período de previsão. Por exemplo, em junho de 2019, de acordo com a Organização Mundial de Saúde (OMS), a epilepsia afetava mais de 50 milhões de indivíduos em todo o mundo. Além disso, a recorrência das crises é causada por uma atividade cerebral anormal. Isto impulsiona o crescimento do mercado.

• Número crescente de desenvolvimentos de medicamentos

Projeta-se que os potenciais medicamentos emergentes em pipeline impulsionem o mercado durante o período de previsão. Por exemplo, em outubro de 2020, a Marinus Pharmaceuticals iniciou um ensaio clínico randomizado para o medicamento Ganaxolona. Este estudo avaliou a eficácia e segurança da ganaxolona IV, para o tratamento de doentes que sofrem de epilepsia.

Oportunidades

• Aumento de lesões na cabeça e cancro cerebral

De acordo com o NCBI, os tumores cerebrais são a segunda causa mais comum de epilepsia na população idosa, resultando em 10% a 30% de todas as causas de epilepsia geriátrica. As convulsões são o sintoma inicial em 20% a 40% dos doentes com tumor cerebral; cerca de 20% a 45% dos doentes podem ter crises epilépticas no decurso da doença. De acordo com a Liga Internacional Contra a Epilepsia (ILAE), as infeções no sistema nervoso central, como a meningite, a encefalite e a neurocisticercose, podem causar convulsões sintomáticas agudas e epilepsia.

• Aumento de iniciativas e financiamento governamental

There have been growing funding between numeorus organizations that can cause market growth. For instance, in March 2021, American Epilepsy Society granted fund for prolonged epilepsy up to US$ 50,000 and are projected to support the establishment of national or global multicenter research initiatives. Each award will provide funding for organisational planning sessions, infrastructure development, or pilot studies, which allows the research programme to compete for future investment.

Restraints/Challenges

• High Cost of Treatment

The augmented expenditure that is required for the multiple treatment processes restrict the market growth. Numerous market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process, and in return, the cost is increased.

This paediatric epilepsy therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the paediatric epilepsy therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2022, UCB announced plans to acquire Zogenix for US$ 1.9 Bn to add Fintepla (Fenfluramine), a marketed drug for treating seizures related to the Dravet syndrome. The transaction adds a newly marketed product for patients with rare and difficult-to-treat pediatric orphan epilepsy syndromes to UCB's extensive therapeutic offerings in the epilepsy market.
• In 2021, Dr. Reddy's Laboratories announced the antiepileptic medication Vigabatrin tablets in the U.S. market after receiving approval from the US FDA.

Global Paediatric Epilepsy Therapeutics Market Scope

The paediatric epilepsy therapeutics market is segmented on the basis of diseases type, therapeutics, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diseases Type

• Benign Rolandic Epilepsy
• Infantile Spasms
• Lennox-Gastaut Syndrome
• Others

Therapeutics

• Surgical Therapies
• Dietary Supplements
• Vagal Nerve Stimulation
• Others

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Paediatric Epilepsy Therapeutics Market Regional Analysis/Insights

The paediatric epilepsy therapeutics market is analyzed and market size insights and trends are provided by disease type, therapeutics, distribution channel and end-user as referenced above.

The major countries covered in the paediatric epilepsy therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market because of the occurrence of key manufacturers of the product is high and, increasing research and development activities.

Asia-Pacific is considered to grow over the upcoming years because of augmented new research and developments on paediatric epilepsy therapeutics market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Paediatric Epilepsy Therapeutics Market  Share Analysis

The paediatric epilepsy therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to paediatric epilepsy therapeutics market

Key players operating in the paediatric epilepsy therapeutics market include:

• GSK Plc. (U.K.)
• Pfizer Inc. (U.S.)
• Medtronic (Ireland)
• UCB S.A. (Belgium)
• NeuroPace, Inc (U.S.)
• Jazz Pharmaceuticals, Inc (U.K.)
• Novartis AG (Switzerland)
• Johnson & Johnson Services, Inc. (India)
• Abbott (U.S.)
• Sage Therapeutics, Inc (U.S.)
• Sunovion Pharmaceuticals Inc (U.S.)
• Sanofi (France)
• Bausch Health Companies Inc. (Canada)
• Amneal Pharmaceuticals LLC (U.S.)

SKU-57393